About NeoChord

About NeoChord

ABOUT US | Company Overview

Who are we?

NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.


J. Alex Martin

Chairman of the Board

A 40-year, veteran corporate executive of the healthcare and medical device industries, Mr. Martin brings an accomplished track record for growing corporate revenue and successfully transforming global businesses. Mr. Martin was the President and CEO of Coherex Medical, where he led the company to a successful exit with Biosense Webster (a Johnson and Johnson company), in November 2015. Prior to Coherex, Mr. Martin was the President and CEO of WorldHeart Corporation, where he led the company to a successful exit with HeartWare in August 2012. Previously, Mr. Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corporation, a Johnson & Johnson Company, and SonaMed Corporation. Mr. Martin holds a bachelor’s degree from the University of Kentucky.

Andrew ElBardissi, M.D.

Board Member

Dr. ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the Private Transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and as presented his research at numerous medical and surgical conferences.

David Gregorka

Board Member

Dave Gregorka is an independent consultant that has been providing his expert advice to Baird Capital since 2013. He works from Baird’s Ann Arbor, Michigan office and provides strategic advice to the General Partner of the partnerships, assists with our evaluation of investment opportunities and works with our team to build value within the existing portfolio.

Dave is an experienced operations executive and entrepreneur who has successfully taken multiple businesses from start-up to commercial success. He is an active member of the Michigan entrepreneurial community and is a Mentor-In-Residence for the University of Michigan Office of Technology Transfer. Dave was previously a co-founder of HealthMedia and held various roles, including the company’s Chief Financial Officer and operations VP. Johnson & Johnson acquired HealthMedia in 2008. In prior roles, he was on the executive management teams of a start-up company that developed tools for managing large data sets and of an international public health and environment standards and certification organization. He chairs the External Advisory Board of the University of Michigan Weil Institute for Critical Care and Research Innovation and serves on the boards of Genomenon and NeoChord. Dave has an MBA and M.S. degree from the University of Michigan and a B.S. from the University of Rochester.

Casey Tansey

Board Member

Mr. Tansey is a managing member of U.S. Venture Partners, a leading Silicon Valley venture capital firm. Mr. Tansey brings significant experience in entrepreneurial, early stage, medical device companies to our NeoChord Board of Directors. Prior to joining USVP, Mr. Tansey was President and CEO of Epicor Medical, a medical device company that developed a minimally invasive treatment for atrial fibrillation and was acquired by St. Jude Medical in 2004. Prior to Epicor, he was President and CEO of Heartport Inc., an innovator of minimally invasive cardiac surgery products. Heartport was acquired by Johnson & Johnson in 2001. Previously, Mr. Tansey served as Vice President, North American Sales for Baxter Edwards’ Cardiovascular products, including heart valves and oxygenators. Mr. Tansey’s educational background includes a B.S. and M.B.A from The College of Notre Dame in Belmont, California.

Mudit K. Jain, PhD

Board Member

Mudit is a Founding General Partner of Treo Ventures (formerly known as Strategic Healthcare Investment Partners-S.H.I.P), and the CEO and co-founder of NuXcel, a medical device accelerator. Mudit also co-founded and serves as Chairman of the Board of ShiraTronics, Inc., a NuXcel spin off company. Mudit has over two decades of medical device industry experience across company formation, R&D, and business development. In addition to his private venture capital experiences at Treo, and Synergy Life Science Partners, Mudit also brings a strategic investment perspective based on his tenure at Johnson and Johnson Development Corporation.

Mudit has served on the boards of several medical device companies, from early to commercial growth stage, resulting in successful IPOs and M&A transactions. Mudit currently serves on the boards of Inspire Medical Systems (NYSE: INSP), Neochord, Inc., ShiraTronics, Inc., CVRx, Inc., and Noctrix, Inc. Some of his prior investments/board responsibilities include Irhythm Technologies (NSDQ:IRTC), Aptus Endosystems (Acqd. by Medtronic), CardioMEMS (Acqd. by St. Jude Medical), Impres Medical (Acqd. by J&J), and Neuspera,Inc. Mudit also serves on the Board of Visitors of the Graduate School at Duke University, External Advisory Board of John Hopkins University Center for Bioengineering Innovation and Design. Prior to his investing career, Mudit held operational roles in the Cardiac Rhythm Management Division of Guidant Corporation, and played a key role in developing novel device technologies for heart failure, remote cardiac monitoring, and cardiac ablation. Mudit holds 8 issued patents and has authored several peer reviewed publications. Mudit graduated with a B.E. in Electrical Engineering from REC, Nagpur, India, where he was a gold medal recipient for academic achievements. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from the Wharton School, University of Pennsylvania.


Todd Berg

Chief Executive Officer

Mr. Berg joined NeoChord in September of 2023 and serves as Chief Executive Officer. Mr. Berg has over 30 years of experience in the medical device industry, most recently service as CEO of Metavention. Prior to Metavention, he was founder, President and CEO of Torax Medical until its acquisition by Johnson & Johnson in 2017. Prior to that, Mr. Berg was with St. Jude Medical, where he was the Vice President of Emerging Technology. He joined St. Jude Medical through the acquisition of Vascular Science in 1999 where he was the Vice President of Research and Development. Before Vascular Science, he was with SciMed Life Systems and Boston Scientific. Mr. Berg holds over 80 patents in medical technology. He received a Bachelor of Science degree in mechanical engineering.

Kavitha Ganesan

Chief Operating Officer

Mrs. Ganesan has 20 years of experience in the medical device industry in various technical and leadership roles. Prior to NeoChord, Mrs. Ganesan led Regulatory and Advanced Therapies at Metavention for a multi-organ denervation platform where she led the company to successful approval of Metavention’s Renal Denervation Pivotal IDE Study. Prior to Metavention, Mrs. Ganesan built and led a structural heart product development program that developed Transeptal Mitral Valve Replacement products at Caisson Interventional, which lead to a successful acquisition by LivaNova. Before that, she held various operational roles within medical device start-ups developing disruptive cardiovascular and interventional therapies. Ms. Ganesan’s educational background includes Master of Science in Bioengineering from Clemson University.  

Adam Ahlstrom

Clinical Affairs, Vice President

Mr. Ahlstrom has nearly 20 years of experience in the medical device industry. Prior to NeoChord, Mr. Ahlstrom’s most recent experience was at Metavention, leading global clinical strategy and execution for multiple studies in various geographies. He has held positions of increasing responsibility at Torax Medical (acquired by Ethicon J&J), ev3 (acquired by Covidien), and AGA Medical (acquired by St. Jude/Abbott). 

Ron M. Nelson

Chief Financial Officer

Mr. Nelson has held various full-time positions in finance with several early-stage medical device startups in the last 30+ years. Mr. Nelson started his career with Touche Ross & Co., an international public accounting firm. Most recently, he was Chief Financial Officer of CHF Solutions, a medical device company prior to their acquisition. Mr. Nelson has extensive experience in finance leadership positions with several global start-up ventures. Mr. Nelson’s educational background includes CPA certification and a Bachelors degree in Business from Gustavus Adolphus College.

Alex Jonkers

Chief Commercial Officer

Mr. Jonkers is a 20 year veteran of the medical device and healthcare industry. Most recently, Jonkers was with Medtronic, Inc., leading a large commercial organization responsible for catheter-based therapies and surgical heart valves across the EMEA region. Prior to Medtronic, he was with CoreValve, Inc., serving in a clinical and sales leadership capacity and a key member of the team that directed the successful integration of CoreValve into the Medtronic organization upon acquisition. Mr. Jonkers’ educational background includes healthcare and business degrees from the Open University Netherlands.

Daryl Edmiston

Chief Technology Officer

Mr. Edmiston has over 15 years of interventional medical device leadership experience. His background includes engineering project management, state-of-the-art manufacturing process development, and medical device design with patents in embolic protection, stent delivery and occlusion devices. He has extensive experience in implementing R&D capabilities in a startup environment, managing intellectual property, and developing technical and design dossiers through clinical trials. Prior to joining NeoChord, Mr. Edmiston was Vice President of Research and Development at Coherex Medical, leading teams from concept development through CE Mark and IDE approval. Prior to Coherex Medical, Mr. Edmiston held leadership roles at Rubicon Medical, directing technical development through clinical trials, CE market clearance and company acquisition. He also held technical roles at Fairchild Semiconductor and Spectra-Physics Laserplane. Mr. Edmiston holds a bachelor’s degree in Mechanical Engineering from Brigham Young University and a master’s degree in Mechanical Engineering from Purdue University.

W. Randolph Chitwood, Jr., MD

Chief Medical Officer

Dr. Chitwood is an internationally known cardiac surgeon, who pioneered robotic and minimally invasive mitral valve surgery. He has 35 years of experience in practicing high volume cardiac surgery, specializing in mitral valve repair. He performed the first complete robotic mitral repair in the United States and led the clinical trials eventuating in FDA approval of the daVinci Surgical System for mitral valve surgery. He has worked with various companies developing innovative technology and participating in clinical trials. These include Intuitive Surgical, Atricure, Scanlan International, Abbott and Edwards Life Sciences. He is a past President of the Society for Thoracic Surgeons, the Heart Valve Society, and the International Society for Minimally Invasive Cardiothoracic Surgery. Dr. Chitwood graduated from Hampden Sydney College (BS) and the University of Virginia (MD). He completed a ten-year residency program in general and cardiothoracic surgery at Duke University. Thereafter, he established the cardiac surgery program at East Carolina University, rising to Chairman of the Department of Surgery and later to become the Founder of the East Carolina Heart institute.

Jenny Donovan

Director, Business Operations

Mrs. Donovan has 20 years of experience in the Medical Device and Pharmaceutical Industry. She began her career at Medtronic where she held various roles in the customer service and IT organizations. Jenny left Medtronic in 2010 to pursue her first start-up opportunity at CNS Therapeutics, a specialty-pharmaceutical company. In 2013, CNS was purchased by Covidien Inc. After a successful transition, Jenny continued her start-up career at InnerSpace Neuro Solutions and then at Global Kinetics Corporation before joining the NeoChord Team in 2015. Jenny specializes in operational leadership for commercial and clinical organizations. She holds a Bachelor of Arts Degree in Biology from Gustavus Adolphus College.
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation.

NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.

NEOCHORD, DS1000, RECHORD, NEOCHORD CONSULTCONNECT, CONNECTCARD, ACCHORD, ULTRACHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of NeoChord, Inc.

CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.


(952) 698-7800


NeoChord, Inc
5402 Parkdale Drive,
Suite 160 St. Louis Park,
MN 55416